Association of SLCO1B3 Polymorphism with Intracellular Accumulation of Imatinib in Leukocytes in Patients with Chronic Myeloid Leukemia
スポンサーリンク
概要
- 論文の詳細を見る
Intracellular concentration of imatinib in leukemic cells is thought to affect the clinical efficacy of this drug in patients with chronic myeloid leukemia (CML); however, there is no report that directly indicates the relationship between intracellular concentration and clinical outcome and/or, plasma concentration. In addition, the impacts of genetic variations of drug transporters, which mediate leukocyte concentration of imatinib, are unknown. In the present study, we investigated the correlation between intracellular imatinib concentrations in leukocytes, plasma imatinib levels, and genotypes of drug transporters, including ATP binding cassette B1 (ABCB), ABCG2, solute carrier 22A1 (SLC22A1), solute carrier organic anion transporter family members 1B1 (SLCO1B1) and SLCO1B3. The imatinib levels in leukocytes were determined using HPLC in 15 patients with chronic phase CML. No significant correlation between intracellular and plasma concentrations of imatinib was observed. The intracellular concentration was comparable in both patients with or without complete cytogenetic response. The intracellular imatinib concentration was significantly higher in patients with SLCO1B3 334TT than in those with 334TG/GG (p=0.0188). Plasma concentrations were similar in both SLCO1B3 genotypes (p=0.860), thereby resulting in the intracellular to plasma concentration ratio being higher in patients with SLCO1B3 334TT than those with 334 TG/GG (p=0.0502). These results suggested that the SLCO1B3 334T>G polymorphism could have a significant impact on the intracellular concentration of imatinib in leukocytes as a promising biomarker for personalized treatment of CML patients.
著者
-
Hamada Akinobu
Kumamoto Univ. Hospital Kumamoto Jpn
-
Hamada Akinobu
Department Of Pharmacy Kumamoto University Hospital
-
Nambu Takeru
Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto
-
Nakashima Reiko
Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto
-
Yuki Misato
Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto
-
Kawaguchi Tatsuya
Department of Hematology and Infectious Diseases, Kumamoto University Hospital
-
Mitsuya Hiroaki
Department of Hematology and Infectious Diseases, Kumamoto University Hospital
-
Saito Hideyuki
Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto
-
Kawaguchi Tatsuya
Department Of Hematology And Infectious Diseases Kumamoto University Graduate School Of Medical Scie
-
Mitsuya Hiroaki
Department Of Hematology And Infectious Diseases Kumamoto University Graduate School Of Medical Scie
-
Nakashima Reiko
Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University
-
Yuki Misato
Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University
-
Saito Hideyuki
Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University
-
SAITO Hideyuki
Department of Clinical Pharmaceutical Sciences, Faculty of Life Science, Kumamoto University
関連論文
- Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma
- Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan
- Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases
- Phase I Study of Intravenous PSC-833 and Doxorubicin: Reversal of Multidrug Resistance
- A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL
- Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors
- Phase III Study of Ranimustine, Cyclophosphamide, Vincristine, Melphalan, and Prednisolone (MCNU-COP/MP) versus Modified COP/MP in Multiple Myeloma : A Japan Clinical Oncology Group Study, JCOG 9301
- Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice
- Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients
- Extragonadal germ cell tumors in Japan
- Treatable Subsets in Cancer of Unknown Primary Origin
- Toxicity and efficacy of ifosfamide, carboplatin and etoposide (modified ICE) as a salvage chemotherapy in Japanese patients with relapsed or refractory aggressive non-Hodgkin's lymphoma
- Association of SLCO1B3 Polymorphism with Intracellular Accumulation of Imatinib in Leukocytes in Patients with Chronic Myeloid Leukemia
- P-Glycoprotein Mediates Efflux Transport of Darunavir in Human Intestinal Caco-2 and ABCB1 Gene-Transfected Renal LLC-PK1 Cell Lines
- TED-AJ03-370 Planar Measurement of Local Characteristics of Impinging Spray on Heating Plate
- Leukemic infiltration of the lung following allogeneic hematopoietic stem cell transplantation
- Hairy cell leukemia responsive to anti-thymocyte globulin used as immunosuppressive therapy for aplastic anemia
- Acute and chronic metabolic acidosis interferes with aquaporin-2 translocation in the rat kidney collecting ducts
- Clinical features of adult acute leukemia with 11q23 abnormalities in Japan : a co-operative multicenter study
- Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase
- A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease
- Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers : A phase I study in Japanese patients
- Trial of intraventricular ribavirin therapy for subacute sclerosing panencephalitis in Japan
- Granulocyte Colony-Stimulating Factor-Primed Donor Lymphocyte Infusion after Salvage Chemotherapy for Treatment of Relapsed Acute Leukemia after Allogeneic Stem Cell Transplantation
- Cytogenetic Abnormalities without Evidence of Relapse after Treatment with Imatinib and Stem Cell Transplantation in a Patient with Ph-Positive ALL
- Acyclothymidine Alleviates Intestinal Toxicity of 5'-Deoxy-5-fluorouridine without Loss of Antitumor Activity in Mice
- Modulation of the Pharmacokinetics of 5'-Deoxy-5-fluorouridine and 5-Fluorouracil in Rats by Oral Co-administration of Acyclothymidine
- Bromocriptine Reverses P-Glycoprotein-mediated Multidrug Resistance in Tumor Cells
- Bromocriptine Reverses P-Glycoprotein-mediated Multidrug Resistance in Tumor Cells
- High-performance liquid chromatographic assay for the simultaneous determination of lansoprazole enantiomers and metabolites in human liver microsomes
- Increase in Doxorubicin Cytotoxicity by Inhibition of P-glycoprotein Activity with Lomerizine
- Pharmacokinetic Differences between Lansoprazole Enantiomers and Contribution of Cytochrome P450 Isoforms to Enantioselective Metabolism of Lansoprazole in Dogs
- Inhibitory Effect of Human Immunodeficiency Virus Protease Inhibtors on Multidrug Resistance Transporter P-Glycoproteins
- Inhibition of 5'-Deoxy-5-fluorouridine Phosphorolysis by Acyclothymidine in Tumor Cell Homogenates
- Roles of Hydrophobicity, Protein Binding and the Probenecid-Sensitive Transport System in the Cerebrospinal Fluid Delivery of Nucleoside Analogues with Anti-viral Activity
- Methotrexate-Loxoprofen Interaction : Involvement of Human Organic Anion Transporters hOAT1 and hOAT3
- Common single nucleotide polymorphisms of the MDR1 gene have on influence on its mRNA expression level of normal kidney cortex and renal cell carcinoma in Japanese nephrectomized patients
- P-39 2'-DEXY-4'-C-ETHYNYL-2-FLUOROADENOSINE, A NRTI THAT COULD BE AN IDEAL DRUG FOR BOTH HIV-AND HBV-INFECTIONS
- Synthesis of the L-Enantiomer of 4'-C-Ethynyl-2'-deoxycytidine(Organic Chemistry)
- Successful treatment of Aspergillus liver abscesses in a patient with acute monoblastic leukemia using combination antifungal therapy including micafungin as a key drug
- Micafungin-induced immune hemolysis attacks
- Long-term Efficacy of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor in Therapy of Aplastic Anemia
- Two Cases Showing Clonal Progression With Full Evolution From Aplastic Anemia-Paroxysmal Nocturnal Hemoglobinuria Syndrome to Myelodysplastic Syndromes and Leukemia
- Roles of Hydrophobicity, Protein Binding and the Probenecid-Sensitive Transport System in the Cerebrospinal Fluid Deliveryof Nucleoside Analogues with Anti-Viral Activity
- Oral Melphalan, Dexamethasone, and Thalidomide for the Treatment of Refractory Multiple Myeloma
- Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia
- New Insights into Molecular Pathogenesis of Bone Marrow Failure in Paroxysmal Nocturnal Hemoglobinuria
- A Novel Type of Factor XI Deficiency Showing Compound Genetic Abnormalities: A Nonsense Mutation and an Impaired Transcription
- Markedly high plasma erythropoietin and granulocyte-colony stimulating factor levels in patients with paroxysmal nocturnal hemoglobinuria
- Sequential development of myelodysplasia and paroxysmal nocturnal hemoglobinuria in a patient with preceding aplastic anemia
- Cyclosporin-responsive pancytopenia and HLA class II alleles of a patient with paroxysmal nocturnal hemoglobinuria
- T-lymphoblastic lymphoma/leukemia cells nagative for CD52 and CD59
- Migration to an inflammatory site in vivo of paroxysmal nocturnal hemoglobinuria lymphocytes
- Molecular and cellular analyses of HLA class II-associated susceptibility to autoimmune diseases in the Japanese population
- Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells
- Involvement of Specific Transport System of Renal Basolateral Membranes in Distribution of Nicotine in Rats
- (3-24) Application of Improved Interferometric Laser Imaging Droplet Sizing (ILIDS) System to Hollow-Cone Sprays((D-3)Diagnostics 3-Applications and Advamced Technolog)
- TRANSPORT CHARACTERISTICS AND CYTOTOXICITY OF AMINOGLYCOSIDE ANTIBIOTICS IN CULTURED KIDNEY EPITHELIAL CELL LINE (LLC-PK_1)
- Goal-Setting Method and Goal Attainment Measures in Physical Therapy for Stroke Patients : a Systematic Review
- Rat Renal Organic Anion Transporter rOAT1 Mediates Transport of Urinary-Excreted Cephalosporins, but not of Biliary-Excreted Cefoperazone
- Pharmacodynamic Modeling of the Entire Time Course of Leukopenia after a 3-Hour Infusion of Paclitaxel
- Thrombopoietin Stimulates Murine Lineage Negative, Scal-1^+, C-Kit^+, CD34^- Cells: Comparative Study With Stem Cell Factor or Interleukin-3
- Evaluation of Percutaneous Absorption of Midazolam by Terpenes
- High-Performance Liquid Chromatographic Assay for the Determination of Nilotinib in Human Plasma
- Na^+-dependent uptake of 1, 5-anhydro-D-glucitol via the transport systems for D-glucose and D-mannose in the kidney epithelial cell line, LLC-PK_1
- Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer
- Assessment of Adverse Reactions and Pharmacokinetics of Ribavirin in Combination with Interferon α-2b in Patients with Chronic Hepatitis C
- Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma : Japan Clinical Oncology Group study (JCOG 9305)
- Prevalence and Factors Associated with Tinnitus : A Community-Based Study of Japanese Elders
- Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer
- Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats
- Decreased Expression of Glucose and Peptide Transporters in Rat Remnant Kidney
- Decreased Cyclosporin A Concentrations in the Absorption Phase Using Microemulsion Preconcentrate Formulation in Rats with Cisplatin-Induced Acute Renal Failure(Biopharmacy)
- The Influence of Polytypic Structures on the Solid-state ^C NMR Spectra of n-Alkanes
- The Relationship between Treatment Time of Gemcitabine and Development of Hematologic Toxicity in Cancer Patients
- Phase I trial of chemoradiotherapy with the combination of S-1 plus cisplatin for patients with unresectable locally advanced squamous cell carcinoma of the head and neck
- Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria : the AEGIS Clinical Trial
- Alleviation of cisplatin-induced acute kidney injury using phytochemical polyphenols is accompanied by reduced accumulation of indoxyl sulfate in rats
- Rapid Amelioration of Hyperglycemia Facilitated by Dasatinib in a Chronic Myeloid Leukemia Patient with type 2 Diabetes Mellitus
- Three Cases of Aggressive Natural Killer Cell Leukemia with a Lethal Hemorrhagic Complication
- Abacavir/Lamivudine versus Tenofovir/Emtricitabine with Atazanavir/Ritonavir for Treatment-naive Japanese Patients with HIV-1 Infection: A Randomized Multicenter Trial
- Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events
- Distinct Interaction of Nilotinib and Imatinib with P-Glycoprotein in Intracellular Accumulation and Cytotoxicity in CML Cell Line K562 Cells